6 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 4 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 3 | 3 | Active not recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Gall Bladder Carcinoma: new trials by email Literature Review of Gall Bladder Carcinoma trials Research Report on Gall Bladder Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Incidental Gallbladder Carcinoma :Incidence and Clinical Significance in Specimens From Routine Cholecystectomies in Sohag Locality histopathology of gall bladder - Gall Bladder Carcinoma | Recruiting | Sohag University | 100 | 2026-09-20 | 2026-10-21 | |
| Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) neoadjuvant chemotherapy, curative surgery - Gall Bladder Carcinoma | Phase 3 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 114 | 2025-01-01 | 2025-04-16 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer | Phase 2 | Completed | Lisata Therapeutics, Inc. | 66 | 2023-05-13 | 2026-09-28 |
| Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer Durvalumab, Tremelimumab, Capecitabine - Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 40 | 2022-05-23 | 2025-05-01 |
| RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION Radio frequency ablation - Bile Duct Neoplasms, Gall Bladder Carcinoma | Unknown | Asian Institute of Gastroenterology, India | 50 | 2021-06-10 | 2022-04-11 | |
| Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection Gemcitabine, Capecitabine - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 3 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 460 | 2018-12-15 | 2018-12-19 |
| Precise Treatment System of Biliary Malignancies Based on Special Disease Database Cholangiocarcinoma, Gall Bladder Carcinoma | Unknown | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 10000 | 2018-05-25 | 2018-04-17 | |
| Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients Durvalumab, Gemcitabine, Cisplatin - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | AIO-Studien-gGmbH | 128 | 2018-05-02 | 2023-06-15 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Merestinib, Cisplatin, Gemcitabine - Advanced Cancer, Metastatic Cancer | Phase 1 | Completed | Eli Lilly and Company | 19 | 2017-02-03 | 2020-05-19 |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma Cisplatin, Gemcitabine, Copanlisib - Biliary Carcinoma, Gall Bladder Carcinoma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 24 | 2016-07-05 | 2021-08-04 |
| Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Gemcitabine, Cisplatin, Capecitabine - Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 3 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 789 | 2014-04-01 | 2025-03-30 |
| Does Timing of Completion Radical Cholecystectomy Determine the Survival in Incidental Carcinoma Gallbladder Curative surgery - Gall Bladder Carcinoma, Survival | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 48 | 2009-01-01 | 2021-11-10 |
Gallbladder Neoplasms (12) · Cholangiocarcinoma (8) · Bile Duct Neoplasms (2) · Neoplasm Metastasis (2) · Biliary Tract Neoplasms (1) · Digestive System Neoplasms (1) · Disease Progression (1) · Gallbladder Diseases (1) · Klatskin Tumor (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1)
Biliary Tract Diseases (12) · Digestive System Diseases (12) · Neoplasms by Site (12) · Biliary Tract Neoplasms (11) · Digestive System Neoplasms (11) · Gallbladder Diseases (11) · Neoplasms (11) · Adenocarcinoma (8) · Carcinoma (8) · Neoplasms by Histologic Type (8) · Neoplasms, Glandular and Epithelial (8) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bile Duct Diseases (2) · Neoplastic Processes (2)
Gemcitabine (6) · Cisplatin (5) · Capecitabine (3) · durvalumab (3) · tremelimumab (2) · Fluorouracil (1) · Folfox protocol (1) · Leucovorin (1) · Neoadjuvant Therapy (1) · Oxaliplatin (1) · Radiofrequency Ablation (1) · copanlisib (1) · merestinib (1)
AIO-Studien-gGmbH (1) · Asian Institute of Gastroenterology, India (1) · Eli Lilly and Company (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Lisata Therapeutics, Inc. (1) · Rajiv Gandhi Cancer Institute & Research Center, India (1) · Sanjay Gandhi Postgraduate Institute of Medical Sciences (1) · Sohag University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (1)
Germany (3) · China (2) · India (2) · United States (2) · Australia (1) · Austria (1) · Denmark (1) · Egypt (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · United Kingdom (1)
Arndt Vogel, Prof. Dr. (1) · Henning Wege (1) · Jianying Lou, MD,PhD (1) · Jingdong Li, MD,PdD (1) · Kristen K Buck, MD (1) · Peng Gong, MD,PhD (1) · Richard D. Kim, M.D. (1) · Salah Al-Batran, Prof. Dr. (1) · Shengping Li, MD,PhD (1) · Shivendra Singh, Mch Surgical gastroenterology (1) · Tianqiang Song, MD,PhD (1) · Wenlong Zhai, MD,PhD (1) · Yinghe Qiu, MD,PhD (1)
PMID 26228433, PMID 33289918, PMID 34499416, PMID 39240508
2017 (1), 2023 (1)